US/UK/Canada

Share

Pick a time period -
Tags ( Active)

AdjuTec Pharma’s APC148 shines at ESCMID congress

At the recent ESCMID congress, organised by the European Society of Clinical Microbiology and Infectious Diseases, AdjuTec Pharma presented a poster highlighting the results of the phase I single ascending dose study for APC148, aimed at tackling antibiotic resistance. With more clinical trials on the horizon, AdjuTec is hopeful that APC148 will prove to be a powerful new tool against multidrug-resistant bacteria.Read the article at biostock.se: https://www.biostock.se/en/2025/04/adjutec-pharmas-apc148-shines-at-escmid-congress/ This is a press release from BioStock - Connecting

BioStock: AdjuTec Pharma joins forces to fight antibiotic resistance

AdjuTec Pharma has launched a research collaboration with India’s Venus Remedies Limited to combat the escalating threat of antimicrobial resistance. With its lead candidate, APC-148, already in phase I trials, AdjuTec aims to breathe new life into – and restore the power of  – existing antibiotics against multidrug-resistant bacteria. This partnership amplifies efforts to address a critical challenge, defined as a global health emergency by the WHO.Read the article at biostock.se: https://www.biostock.se/en/2025/03/adjutec-pharma-joins-forces-to-fight-antibiotic-resistance/ This is a

AdjuTec Pharma’s CEO to BioStock: “Our goal is to set a new standard in antibiotic treatment”

Late last year, AdjuTec Pharma launched a phase I clinical trial for its lead candidate, APC148, targeting antimicrobial resistance, AMR. Recently, seasoned life science executive Jethro Holter stepped into the CEO role. BioStock talked with Holter to discuss his decision to join AdjuTec Pharma, exploring his vision for the company and the role APC148 could play in tackling the global AMR challenge.Read the full interview with Jethro Holter at biostock.se: https://www.biostock.se/2025/02/adjutec-pharmas-ceo-our-goal-is-to-set-a-new-standard-in-antibiotic-treatment/ This is a press

BioStock: AdjuTec Pharma enters phase I with novel AMR treatment

AdjuTec Pharma has launched a phase I clinical trial for its leading candidate, APC148, targeting a critical unmet need in combating antimicrobial resistance. This move into human trials is a significant milestone in demonstrating the safety and therapeutic potential of APC148, positioning AdjuTec as a key player in the fight against high-priority drug-resistant infections. CEO Bjørn Klem comments on the company’s strategy going forward.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/adjutec-pharma-enters-phase-i-with-novel-amr-

BioStock: AdjuTec Pharma to start phase I trial with APC148

Adjutec is set to start its phase I clinical trial for the enzyme inhibitor APC148, marking a significant milestone for the company. The trial begins September 18 with CTC in Uppsala and will focus on assessing the candidate’s safety. With this step, AdjuTec moves from years of preclinical research into clinical-stage development, targeting the global issue of antibiotic resistance.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/adjutec-pharma-to-start-phase-i-trial-with-apc148/ This is a press release from BioStock - Connecting

BioStock: AdjuTec advances toward phase I with regulatory green light

Preparing to hit the clinical stage with its antibiotic resistance breakers, Norwegian AdjuTec Pharma recently got a goahead from the Swedish Medical Products Agency. The company now hopes to begin single ascending dose studies after the summer break. – The team has done a great job in preparing the clinical trial application. We have had a good dialogue with the Swedish authorities and the process has been really smooth, CEO Bjørn Klem tells BioStock.Läs hela artikeln på biostock.se : https://www.biostock.se/en/2024/05/adjutec-advances-toward-phase-i-with-

BioStock: Adjutec applies for phase I start

Norwegian AdjuTec Pharma prepares for clinical trials with its concept for battling antimicrobial resistance. The company recently raised 16 MNOK and sent a clinical trial application to swedish autorities, aming to start phase I this summer. BioStock contacted CEO Bjørn Klem to get an update.Read the full article at biostock.se : https://www.biostock.se/2024/02/adjutec-applies-for-phase-i-start/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: New proposal potential game changer for Adjutec Pharma

A group of experts from the DRIVE-AB project has introduced a new plan to boost the fight against antimicrobial resistance in the EU and EEA. This pan-European proposal aims to establish a strong incentive model for the development and accessibility of new antimicrobials — a move that could provide support for drug developers like Norwegian Adjutec Pharma.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/new-proposal-potential-game-changer-for-adjutec-pharma/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Adjutec CEO on preparing for phase I

AdjuTec Pharma is pioneering in the realm of antimicrobial resistance with its work rooted in research from the University of Oslo. With its lead product APC148, the biotech firm is edging closer to clinical studies. BioStock talked to CEO Bjørn Klem for an update on the latest developments in the company.Read the full article at biostock.se : https://www.biostock.se/2023/11/adjutec-ceo-on-preparing-for-phase-i/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: AdjuTec takes on global antimicrobial resistance

AdjuTec Pharma is determined in its mission to address the escalating issue of antimicrobial resistance. Stemming from research at the University of Oslo, the company is now advancing towards creating adjuvant technologies to neutralise key bacterial resistance mechanisms. The company is currently heading towards phase I studies with its main candidate APC148.Read the article at biostock.se: AdjuTec takes on global antimicrobial resistance - BioStock This is a press release from BioStock - Connecting

BioStock Investor Meeting: AdjuTec Pharma

AdjuTec Pharma presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners.See the presentation via: BioStock Investor Meeting September 2023 | AdjuTec Pharma - YouTube  See the interview via:  BioStock Investor Meeting | Interview with AdjuTec Pharma | September 2023 - YouTube  This is a press release from BioStock - Connecting Innovation &

BioStock: AdjuTec CEO aims for better and safer antibiotics

Norwegian pharmaceutical company AdjuTec Pharma is on a mission to combat the growing threat of antimicrobial resistance. The company is developing antibiotic resistance breakers, focusing on β-lactamase inhibitors. BioStock contacted CEO Bjørn Klem to learn more about the development and what lies ahead for the company.Read the full article at biostock.se : https://www.biostock.se/2023/09/adjutec-ceo-aims-for-better-and-safer-antibiotics/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe